NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Akebia Therapeutics Inc is a micro cap company (market value under $300 million) in the Drug Manufacturers - Specialty & Generic industry.
Akebia Therapeutics develops and commercializes treatments for kidney disease patients. The company markets Vafseo, an oral medicine for anemia in dialysis patients, and Auryxia, which manages phosphorus levels and iron deficiency anemia in chronic kidney disease. Akebia also maintains a pipeline of mid-stage and early-stage programs targeting rare kidney diseases and other conditions.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Akebia Therapeutics Inc stock.
Undervalued: intrinsic value $0.97 per share, market price $0.40, margin of safety 58.7% (as of 2026-11-17).
Discounting its cash flows at 6.9% (average of 2 methods) values the shares at $0.97; the price of $0.40 is 59% below that value, and 81% of that value comes from beyond year five.
17 more funds hold it; the full list is part of the paid plan.
All 82 Drug Manufacturers - Specialty & Generic stocks
AKBA is undervalued (as of the 2026-11-17 close). Discounting its cash flows at 6.9% (average of 2 methods) values the shares at $0.97; the price of $0.40 is 59% below that value, and 81% of that value comes from beyond year five.
$0.97 per share (as of the 2026-11-17 close), against a market price of $0.40. That is a margin of safety of 58.7%. The value is the average of the 2 valuation methods that apply to this company, recomputed every night after the US close.